The New York startup has built AI that reads handwritten fax forms, processes prior authorisations, and completes patient intakes in under five minutes, all without asking providers to change how they work. It has reached multiple millions in revenue i…
The Eindhoven neurotechnology company is using the proceeds to fund its Empower BP pivotal trial, which tests whether its implantable ARC-IM® system can treat blood pressure instability after spinal cord injury, while expanding commercial rollout of it…
The European Investment Bank is lending €20 million to BioLamina, the Swedish biotech that supplies the laminin-based cell culture matrices used by stem cell therapy developers worldwide. The funding will support expanded production of laminin technolo…
STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by existing investors including Pfizer Ventures and M Vent…
Amazon Web Services (AWS) announced this Tuesday the launch of its AI bio tool, Amazon Bio Discovery, to accelerate the early-stage process of drug discovery in the pharmaceutical industry. The application aims to help scientists design and test novel…
The Kardia 12L, which uses five electrodes and a single cable to replace bulky 10-lead ECG carts, has received CE Mark. It launches first in France, Germany, Italy, Spain, and the UK, with its AI system detecting 35 cardiac conditions including acute m…
Science Corporation, the BCI company founded by ex-Neuralink president Max Hodak, is preparing to place a pea-sized, 520-electrode sensor on a human brain’s surface during already-scheduled surgery. Yale neurosurgery chair Murat Günel will lead the pro…
The Luxembourg-founded startup is already in production with multiple top-20 global pharma companies, including a public collaboration with Pfizer. Its $10M seed round is led by redalpine, with the CEOs of Cohere and HuggingFace among the angel investo…
The drug discovery revolution is real but radically overstated, the health chatbots are a documented hazard, and the diseases that matter most remain stubbornly unsolved. At Novartis, sometime in late 2025, a team of researchers working on Huntington’s…
The case for AI prescription renewals is real. So is the case against trusting a state sandbox to catch the risks. In January, a security research firm called Mindgard sat down with a chatbot. The chatbot had been built by Doctronic, a health technolog…